Low 21-gene expression score associated with low risk of breast cancer recurrence
the ONA take:
Patients with hormone receptor-positive, HER2-negative, axillary node-negative breast cancer and a favorable 21-gene expression assay score had very low rates of disease recurrence at 5 years with endocrine therapy alone, initial results of the TAILORx study published online ahead of print in The New England Journal of Medicine have shown.
For the study, 10,253 eligible women with breast cancer were enrolled. Of those, 1,626 women had a recurrence score of 0 to 10 who were assigned to receive endocrine therapy alone without chemotherapy.
Results showed that 5-year invasive disease-free survival rate was 93.8% (95% CI: 92.4, 94.9), the rate of freedom from recurrence of breast cancer at a distant site was 99.3% (95% CI: 98.7, 99.6), and the rate of freedom from recurrence at a distant or local-regional site was 98.7%. Researchers found that the overall survival rate was 98.0% (95% CI: 97.1, 98.6).
"The compelling results seen in this global study provide unequivocal evidence supporting the clinical utility of Oncotype DX to risk-stratify patients with early stage breast cancer, and indicate that the findings are generalizable to everyday clinical practice," said lead author Joseph A. Sparano, MD, vice-chairman of medical oncology at Montefiore Einstein Center for Cancer Care, and professor of medicine and of obstetrics, gynecology, women's health at Albert Einstein College of Medicine.
Patients with HER2-negative, axillary node-negative breast cancer and favorable 21-gene expression assay score had low rates of recurrence.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
- Pediatric Patients, Parents Overreport Adherence to ALL Medication Regimen
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- National Health Care Spending Expected to Grow Five Percent Annually
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|